Explores IRAK4 inhibitors in diffuse large B-cell lymphoma, suggesting new treatment options.
We report the discovery of a new series of 3 H -spiro[benzofuran-2,4′-piperidine] IRAK4 inhibitors as potential anti-DLBCL agents.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: